Biogen Inc.
BIIB Healthcare Drug Manufacturers - General NASDAQ
$181.30
$-0.68 (-0.37%)
Open: $181.96 | High: $183.15 | Low: $181.10 | Prev Close: $181.98
Market Cap: $26.60B
Volume: 1.1M | Avg: 1.8M
Last updated: December 05, 2025 at 10:00 PMInvestment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 545
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 16.53 |
| P/B Ratio | 1.46 |
| P/S Ratio | 2.64 |
| EPS | $10.97 |
| Beta | 0.13 |
| Shares Outstanding | 146.70M |
| 52-Week High | $185.17 |
| 52-Week Low | $110.04 |
| SMA 50 | $156.99 |
| SMA 200 | $138.23 |
| Next Earnings | January 29, 2026 12:00 PM ET |
Financial Ratios
| Gross Margin | 72.4% |
| Operating Margin | 23.7% |
| Net Margin | 16.0% |
| ROE | 9.3% |
| ROA | 5.5% |
| Debt/Equity | 0.36 |
| Current Ratio | 2.72 |
| Quick Ratio | 2.04 |
Balance Sheet
| Total Assets | $28.05B |
| Total Liabilities | $11.33B |
| Total Equity | $16.72B |
| Cash | $2.38B |
| Total Debt | $6.63B |
| Net Debt | $4.26B |
Income Statement
| Revenue | $9.68B |
| Gross Profit | $7.37B |
| Operating Income | $2.49B |
| Net Income | $1.63B |
| EBITDA | $3.00B |
| Revenue/Share | $68.66 |
Cash Flow
| Operating CF | $2.88B |
| CapEx | $359.80M |
| Free Cash Flow | $2.52B |
| Book Value/Share | $124.20 |
| Tangible Book/Share | $16.27 |
| Equity/Share | $124.20 |
Technical Indicators
| RSI (14) | 75.78 Overbought |
| MACD |
7.78
Signal: 7.29
|
| Volatility | 25.71% |
| Trading Signal | Overbought |
Performance & Returns
| 1 Year | +32.65% |
| Sharpe Ratio | 1.1 Good |
| Volatility (Ann.) | 33.74% Moderate |
| BIIB (1Y) | +32.65% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | +20.78% |
Sector Comparison (Healthcare)
| Metric | BIIB | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 16.53 | 31.46 | 25% |
| P/B Ratio | 1.46 | -0.58 | 20% |
| ROE (%) | 9.25% | 9.81% | 30% |
| Net Margin (%) | 15.98% | 9.95% | 67% |
| Stock Score | 545 | 503.0 | 67% |
| 1Y Return (%) | +32.65% | +3.94% | 88% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIIB | $181.30 | $180.56 | $180.44 | $176.03 | $156.99 | $138.23 | 75.78 | 7.78 | 25.71% | 1246342 | Strong Long | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the BIIB stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| BIIB | Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 | Neutral | globenewswire.com | Read More |
| BIIB | Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| BIIB | Biogen Inc. $BIIB Stake Reduced by Fisher Asset Management LLC | Neutral | defenseworld.net | Read More |
| BIIB | New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF | Neutral | globenewswire.com | Read More |
| BIIB | Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
Company Information
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| CEO | Christopher A. Viehbacher |
| Employees | 7605 |
| Country | US |
| IPO Date | 1991-09-17 |
| Exchange | NASDAQ |
| Website | https://www.biogen.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category